Literature DB >> 2881944

Renal response to intravenous somatostatin in insulin-dependent diabetic patients and normal subjects.

J Vora, D R Owens, S Luzio, J Atiea, R Ryder, T M Hayes.   

Abstract

The acute effects of iv somatostatin (SRIH; 100 micrograms/h) on the urinary flow (Uvol), effective renal plasma flow (RPF), and glomerular filtration rate (GFR) were compared with those of a control infusion of 0.15 M NaCl in nine insulin-dependent diabetic (IDD) patients of less than 10 yr disease duration and six normal subjects (NS). RPF and GFR were measured using a standard primed constant isotope infusion of [125I]iodohippurate and [51Cr]chromium EDTA. Uvol, RPF, and GFR were measured during 20-min clearance periods. During the NaCl infusion mean Uvol, RPF, and GFR were 14.1 +/- 0.2 (+/- SEM), 708 +/- 4, and 150 +/- 1 mL/min in the IDD group and 12.7 +/- 0.4, 568 +/- 5, and 110 +/- 2 mL/min in the NS group, respectively. In the IDD patients Uvol, RPF, and GFR decreased from 16.6 +/- 1.8, 670 +/- 30, 146 +/- 4 mL/min pre-SRIH to 9.2 +/- 1 (P less than 0.001), 553 +/- 25 (P less than 0.001), and 130 +/- 5 (P less than 0.001) mL/min, respectively, at 120 min during the SRIH infusion. Similarly, in the NS group mean Uvol, RPF, and GFR were 14.2 +/- 0.6, 552 +/- 15, and 112 +/- 5 mL/min pre-SRIH and decreased to 7.4 +/- 0.6 (P less than 0.001), 422 +/- 7 (P less than 0.001), and 93 +/- 3 (P less than 0.001) mL/min, respectively, after 120 min of the SRIH infusion. SRIH, therefore, had a profound effect on renal function in both IDD patients and NS, resulting in a reduction in RPF, GFR, and, as a consequence, Uvol.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2881944     DOI: 10.1210/jcem-64-5-975

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  9 in total

Review 1.  Potential pharmacological interventions in polycystic kidney disease.

Authors:  Amirali Masoumi; Berenice Reed-Gitomer; Catherine Kelleher; Robert W Schrier
Journal:  Drugs       Date:  2007       Impact factor: 9.546

2.  Effect of somatostatin on kidney function and vasoactive hormone systems in health subjects.

Authors:  T Tulassay; Z Tulassay; W Rascher; L Szücs; H W Seyberth; I Nagy
Journal:  Klin Wochenschr       Date:  1991-08-01

Review 3.  Glomerular hyperfiltration.

Authors:  Monica Cortinovis; Norberto Perico; Piero Ruggenenti; Andrea Remuzzi; Giuseppe Remuzzi
Journal:  Nat Rev Nephrol       Date:  2022-04-01       Impact factor: 42.439

4.  Somatostatin analogue administration prevents increase in kidney somatomedin C and initial renal growth in diabetic and uninephrectomized rats.

Authors:  A Flyvbjerg; J Frystyk; O Thorlacius-Ussing; H Orskov
Journal:  Diabetologia       Date:  1989-04       Impact factor: 10.122

5.  Effect of the new somatostatin analogue SMS 201-995 on exogenously used insulin.

Authors:  M Bayraktar; A Usman; Z Koray
Journal:  Clin Investig       Date:  1994-09

6.  Effect of octreotide and insulin on manifest renal and glomerular hypertrophy and urinary albumin excretion in long-term experimental diabetes in rats.

Authors:  H Grønbaek; B Nielsen; R Osterby; A Harris; H Orskov; A Flyvbjerg
Journal:  Diabetologia       Date:  1995-02       Impact factor: 10.122

7.  Somatostatin receptor subtype 2-mediated uptake of radiolabelled somatostatin analogues in the human kidney.

Authors:  Edgar J Rolleman; Peter P M Kooij; Wouter W de Herder; Roelf Valkema; Eric P Krenning; Marion de Jong
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-06-02       Impact factor: 9.236

8.  Octreotide-LAR in later-stage autosomal dominant polycystic kidney disease (ALADIN 2): A randomized, double-blind, placebo-controlled, multicenter trial.

Authors:  Norberto Perico; Piero Ruggenenti; Annalisa Perna; Anna Caroli; Matias Trillini; Sandro Sironi; Antonio Pisani; Eleonora Riccio; Massimo Imbriaco; Mauro Dugo; Giovanni Morana; Antonio Granata; Michele Figuera; Flavio Gaspari; Fabiola Carrara; Nadia Rubis; Alessandro Villa; Sara Gamba; Silvia Prandini; Monica Cortinovis; Andrea Remuzzi; Giuseppe Remuzzi
Journal:  PLoS Med       Date:  2019-04-05       Impact factor: 11.069

9.  Long-acting somatostatin analogue treatments in autosomal dominant polycystic kidney disease and polycystic liver disease: a systematic review and meta-analysis.

Authors:  Joshua Griffiths; Mark T Mills; Albert Cm Ong
Journal:  BMJ Open       Date:  2020-01-09       Impact factor: 2.692

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.